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High-resolution SNP arrays in mental retardation
diagnostics: how much do we gain?
Laura Bernardini1, Viola Alesi1,2, Sara Loddo1,2, Antonio Novelli1, Irene Bottillo1, Agatino Battaglia3, Maria
Cristina Digilio4, Giuseppe Zampino5, Adam Ertel2, Paolo Fortina*,2,6, Saul Surrey7 and Bruno Dallapiccola1
We used Affymetrix 6.0 GeneChip SNP arrays to characterize copy number variations (CNVs) in a cohort of 70 patients
previously characterized on lower-density oligonucleotide arrays affected by idiopathic mental retardation and dysmorphic
features. The SNP array platform includes B900000 SNP probes and 900000 non-SNP oligonucleotide probes at an average
distance of 0.7Kb, which facilitates coverage of the whole genome, including coding and noncoding regions. The high density of
probes is critical for detecting small CNVs, but it can lead to data interpretation problems. To reduce the number of false
positives, parameters were set to consider only imbalances 475Kb encompassing at least 80 probe sets. The higher resolution
of the SNP array platform confirmed the increased ability to detect small CNVs, although more than 80% of these CNVs
overlapped to copy number ‘neutral’ polymorphism regions and 4.4% of them did not contain known genes. In our cohort of 70
patients, of the 51 previously evaluated as ‘normal’ on the Agilent 44K array, the SNP array platform disclosed six additional
CNV changes, including three in three patients, which may be pathogenic. This suggests that about 6% of individuals classified
as ‘normal’ using the lower-density oligonucleotide array could be found to be affected by a genomic disorder when evaluated
with the higher-density microarray platforms.
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INTRODUCTION
Copy number variations (CNVs) are defined as DNA changes41Kb
that differ among individuals. They include duplications or deletions
and can involve large DNA regions.1–3 CNVs have an important role
in modulating the phenotypic spectrum both in single gene and
multigenic diseases.3 They are not randomly distributed across the
genome, and their presence correlates with chromosomal structural
features (eg, inverted repeats, duplications, highly homologous regions
and so on).2,4–8
In the past few years, DNA microarrays have increased capabilities
for the detection of both pathological and neutral polymorphic
variations by analyzing the entire genome with a resolution depending
on the number, length and type of probes.1,9–14 Genome tiling
microarrays are now available, allowing DNA analysis at an inter-
mediary resolution between cytogenetic techniques (Z5Mb) and
conventional DNA sequence analysis (1–800 bp).9
Mental retardation (MR) is a relatively frequent disorder affecting
about 3% of the general population. MR etiological diagnoses are
made usually in fewer than half of the affected individuals.15 Genetic
causes account for 17.4–47.1% of cases, with reported frequencies also
varying on the basis of the different techniques used for analysis.15,16
Several years ago, microarray platforms were used for the first time in
clinical genetics, showing that abnormalities in genomic copy number
account for about 10–15% of patients affected by MR, especially when
it is associated with multiple congenital anomalies (MCA) and/or
dysmorphism.17 Microarrays represent a robust and high-resolution
method of analysis. The recent increase in various commercially
available microarray platforms encouraged their application in diag-
nostic settings, and it is expected to improve procedures for the
establishment of genetically determined MR etiology.18 Among com-
mercial platforms, SNP arrays offer the highest resolution using
approximately two million probes. These arrays were originally
designed for genome-wide genotyping, but they can also be used to
detect CNV.19 This approach involves only one DNA sample to be
hybridized on the chip. Software is then used to reveal copy number at
each locus quantifying the fluorescent signal intensity and comparing
it with HapMap controls (International HapMap Project, 2005; http://
www.hapmap.org/). One limitation of these arrays is that probe
selection is not homogeneous, as it reflects the distribution of SNPs
in the genome, and SNPs are very sparse in genomic segments
containing low-copy repeats and segmental duplications.9 SNP arrays
frequently offer a better detection of CNVs in gene-poor regions.20 To
overcome this restriction, the latest generation high-resolution SNP
array platforms were generated by adding nonpolymorphic sequences
to cover the SNP-poor region (Illumina, San Diego, CA, USA and
Affymetrix, Santa Clara, CA, USA). For example, the Affymetrix 6.0
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GeneChip consists of both 906 600 SNP sequences and about 900 000
nonpolymorphic oligonucleotides, with an overall spacing of 1
sequence per 700 bp along the entire genome.21 The theoretical
resolution of a microarray depends on the length, number and
genomic density of probes; however, many other parameters can
determine the practical resolution, including the level of experiment
noise and the sensitivity of copy number measurements.9,22,23 Thus, in
oligonucleotide arrays as in SNP arrays, the reduced length of probes
tends to generate a lower signal-to-noise ratio of hybridization, and
analyses need to average data from several consecutive spotted
sequences, thus diminishing the overall resolution.9
In this study, we analyzed 70 karyotyped patients affected by MR/
MCA, who were previously analyzed with an oligonucleotide array
with an average spacing of 32 kb. CNVs detected by SNP array were
selected following the workflow as previously suggested,24 and they
were verified systematically by other techniques (fluorescence in situ
hybridization (FISH) and/or quantitative-PCR (qPCR)). The purpose
of this study was to assess Affymetrix GeneChip 6.0 array sensitivity in
CNV detection to establish the effective resolution of this platform
and to explore the role of CNVs in the definition of as-yet-un-
explained MR patients. In particular, we intended to evaluate the
potential diagnostic usefulness of this technique coupling a more
sensitive chip with strict clinical criteria.
MATERIALS AND METHODS
Patients
A total of 70 patients were evaluated. They were selected from the cohort of
subjects referred to our diagnostic laboratory for CNVs analysis in the 2006–
2007 2-year period. All individuals were karyotyped (4450 band resolution):
64 had a normal karyotype, 5 had apparently balanced structural rearrange-
ments and 1 patient had a subtelomeric rearrangement detected by FISH
analysis. Diagnostic screening was performed using an oligonucleotide-based
array (44K – AMADID 014950; Agilent Technologies, Walldbron, Germany). A
total of 19 patients were positive in this initial screening. This group of
individuals (SET I) was used for validation purposes. The remaining 51
patients (SET II) were analyzed to assess whether the higher resolution of
GeneChip 6.0 resulted in an effective higher sensitivity in detecting smaller
pathogenic CNVs in these individuals. These two platforms were comparable in
terms of the cost and timetable of a single experiment. All studies were
approved by the Institutional Review Board committee and conducted with
patients’ informed consent. All patients were affected by moderate-to-severe
MR (QIo50), showed dysmorphic features and/or developmental delay and/or
had at least one major severe congenital malformation and/or multiple mild
congenital anomalies. A commercially available NucleoSpin Blood kit (Macherey-
Nagel GmbH & Co, Du¨ren, Germany) was used to extract genomic DNA from
2ml of peripheral blood.
Controls
A data set of genotype and copy number calls on 270 control samples from the
International HapMap Project was used (http://www.hapmap.org/). The SNP
6.0 copy number calls from these HapMap samples were provided by
Affymetrix as a reference model file for use in Genotyping Console software
(Affymetrix).
Affymetrix GeneChip mapping 6.0 microarray
The GeneChip 6.0 platform consists of about 906 600 SNP sequences and about
900 000 nonpolymorphic oligonucleotides, which cover the whole genome with
an average spacing of 0.7 Kb. In two separate reactions, genomic DNA (250ng)
was digested with NspI or StyI (New England Biolabs, Ipswich, MA, USA), as
recommended by the manufacturer (Affymetrix). After digestion, an adaptor
was linked to the restricted fragments, the reaction was diluted 4 and the
fragments were amplified by PCR. After purification using Magnetic Beads
(Agencourt Bioscience Corporation, Beverly, MA, USA), 90mg of PCR products
was fragmented and end labeled using 30U/ml of terminal deoxynucleotidyl
transferase, and then hybridized for 16–18 h to the Affymetrix 6.0 chip at 491C
in a GeneChip Hybridization Oven 640 (Affymetrix). The chips were washed,
stained in GeneChip Fluidic Station 450 (Affymetrix) and scanned with
Scanner 3000 7G (Affymetrix).
Genotype and copy number calls
Affymetrix CEL files were loaded into Genotyping Console (GTC) 3.0.1 for
genotype and copy number analysis. The GTC Contrast Quality Control (QC)
metric was used to filter out low-quality samples using the default threshold of
0.4. Copy number analysis, using the Affymetrix HapMap270 Reference Model
File for comparison, was performed with the default settings in GTC, including
regional GC correction. Detailed descriptions of the algorithms implemented
by GTC copy number analysis are provided in Korn et al.25 Briefly, GTC applies
the BRLMM-P Plus algorithm, which uses a one-dimensional Gaussian
mixture model to establish the intensity of each genotype and copy number
probe at discrete levels relative to the reference model file. A Hidden Markov
Model is then applied for smoothing the copy number data on the basis of
neighboring values in a region.
Copy number segment analysis
The GTC segment-reporting tool was supplied to identify regions in the
genome with a default setting of at least 25 markers showing consensus for
gain or loss spanning at least a 75-kb region. Data for regions meeting these
criteria were exported for further analysis in Microsoft Excel. These results
of the segment analysis were used to compare aberrant regions against
known copy number polymorphisms and select copy variations for validation.
The copy number aberrations were further filtered to select CNVs more likely
to be pathogenic on the basis of the size and number of markers in the region.
A CNV was scored when it encompassed 475Kb and included at least 80
markers. Considering that the average spacing of the targets of this array
is 0.7Kb, one would expect roughly 107 SNP markers ((1 SNP/0.7 kb)75 kb¼
107 SNPs). The smallest CNVs were considered only when at least 75% of the
CNV length was covered by markers.
Validation of CNVs
The database of Genomic Variants (http://projects.tcag.ca/variation/), UCSC
Genome browser (http://www.genome.ucsc.edu/) and DECIPHER (http://
www.sanger.ac.uk/PostGenomics/decipher), were used to identify known geno-
mic variants, genes and MR-associated regions. Each CNV containing known
genes and/or miRNA sequences not found in controls was attempted to be
confirmed by other methods. FISH analysis was used to confirm deletions
4150Kb and duplications 4400Kb, whereas custom quantitative-PCR assay
was used to confirm smaller CNVs.
FISH
To confirm new imbalances, appropriate BACs (bacterial artificial chromo-
somes) were selected from a genome-wide 32K BAC library (BACPAC
Resources Center, Children’s Hospital Oakland Research Institute, Oakland,
CA, USA) (http://www.chori.org/bacpac). Probes were prepared and FISH was
performed as previously described.26 An Eclipse 80i fluorescence microscope
equipped with a computerized system (Genikon; Nikon, Florence, Italy) was
used to analyze and acquire images. To confirm an imbalance, about 30
metaphase spreads and/or nuclei for each sample were counted.
qPCR
Smaller sized DNA copy number changes were confirmed using an AB 7000
Sequence Detection System (Applied Biosystem, Foster City, CA, USA) and
DNA-binding dye SYBR Green (Invitrogen Corporation, Carlsbad, CA, USA)
as described by Carbone et al.27
X-inactivation assay
The X-chromosome inactivation pattern in patient 29 was assessed by studying
the methylation state of the androgen receptor gene.28 PCR products were
separated on an ABI Prism 3100 DNA sequencer and analyzed using GeneScan
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version 3.5.1 (Applied Biosystems) and Genotyper software version 2.1.5
(Applied Biosystems).
RESULTS
This study focused on testing for CNVs in patients with MR on a
high-resolution SNP array platform consisting of about 1 800 000
probes including polymorphic and nonpolymorphic sequences. A
total of 70 MR/MCA patients were hybridized on a GeneChip 6.0
platform and data were analyzed using Genotyping Console software
(GTC v3.0.1). SNP array analysis detected the presence of CNVs in all
patients with a highly variable number ranging from 10 to 313 per
subject.
Using filters described in Materials and Methods, an average of 21
CNVs were detected in each sample (range 8–41), with a size range of
0.76–16.314Mb. This number was reduced further, following the
recommendations of Koolen et al.24 CNVs were not considered as
pathogenic if the rate of overlap with known nonpathogenic poly-
morphic CNVs was 450–70% (81% of CNVs and 100% of CNVs
smaller than 100 kb), or if the CNV did not involve known genes
(4.4% of nonpolymorphic CNVs). CNVs with a probe densityo2 kb
were excluded as well. These rules were not considered for CNVs
affecting regions known to be involved in microdeletion/microdupli-
cation syndromes and for X-linked CNVs occurring in male patients.
All selected CNVs were confirmed using other techniques and, when
possible, this test was expanded to parents to distinguish between de
novo-generated and inherited CNVs. Clinical features, SNP array
results, standard karyotypes and array-CGH data of patients are
summarized in Table 1. The number of probes present in each affected
chromosome region, their density, degree of overlap with known
common CNV regions, confirmation technique and CNV origin are
also listed.
SET I
This set included the 19 patients previously shown to be positive for
copy number changes using oligonucleotide array analysis. SNP array
analysis confirmed the presence of all CNVs previously detected: 14
deletions ranging in size from 0.257 to 6.494Mb and 9 duplications of
0.583–7.930Mb. In total, seven patients (1, 4, 7, 8, 13, 16 and 18)
displayed a pathogenic deletion, including the subtelomeric deletion
of 1p, 2q and 9q. A total of five patients (2, 9, 10, 12, 15) had a
duplication including the MECP2 duplication, and duplication of the
proximal 15q region associated with autism in two subjects. Patient 6
was shown to be the carrier of two losses on both analyses: deletion of
4.9Mb at 3q23q24, near the break point of a de novo reciprocal
translocation (3; 21), and deletion of about 3.2Mb at 11p11.2. Patient
11 had a terminal deletion and associated duplication of two con-
tiguous regions at 10pter, whereas Patient 17 harbored a terminal
deletion associated with a contiguous duplication on chromosome 1
(Figure 1).
In four patients (3, 5, 13 and 19), SNP array analysis showed
additional CNVs not detected by the oligonucleotide array. Patient 3
had a 1.4-Mb deletion of 3p25.3p25.2 on both platforms, whereas the
SNP array disclosed an additional 0.871-Mb duplication of 18q22.1,
which proved to be maternally inherited by FISH analysis. Patient 5
disclosed the duplication of two separate but neighboring
regions (3.494 and 6.091Mb) on chromosome 5q, confirmed by
FISH (Figure 2a and b). These duplications were shown to derive
from the malsegregation of a complex balanced paternal rearrange-
ment involving chromosomes 3, 5 and 11 (Figure 2c). SNP arrays also
showed a duplication of 0.140Mb at Xq13.1, considered to be a false-
positive result, as qPCR performed on PJA1 disclosed only two copies
similar to that in controls. Patient 13 showed a 0.373-Mb subterminal
deletion at 9q34.3 on both analyses, in addition to a paternally
inherited gain of 0.684Mb at 1q43 (ZP4 gene) on SNP arrays. Patient
19 showed a de novo gain of 0.188Mb at 5q14.3, encompassing the
CETN3 gene, in addition to a deletion at 1p35.3p35.2 disclosed by
both platforms.
SET II
This set included 51 samples previously found to be negative for copy
number changes using oligonucleotide arrays. A total of 48 patients
showed no CNV change after SNP array analysis. Three samples (29,
54 and 66) were positive on SNP arrays, disclosing CNVs ranging in
size from 0.352 to 0.583Mb. In patient 29, the SNP array showed a
duplication of 0.583Mb at Xp11.4 containing two genes (TSPAN7 and
MID1IP1) (Figure 3a). Although the parents’ DNA was not available
to assess the origin of this imbalance, an X-inactivation assay showed a
random inactivation of X chromosomes (68%) (Figure 3a). Patient 54
showed a deletion of 0.545Mb at 9q33.1 involving TRIM32 and
ASTN2 (Figure 3b), which was not present in his mother, whereas
the father’s DNA was not available to elucidate the origin of CNV. In
patient 66, the SNP array disclosed a de novo duplicated region of
about 0.52Mb containing three known genes (ANKRD56, SEPT11
and CCNI) at 4q21.1 (Figure 3c).
DISCUSSION
Microarray-based platforms to be applied in diagnostic practice
require a high level of robustness, reproducibility and effective
resolution in detecting CNVs. Hehir-Kwa et al, performed a statistical
power analysis to compare four different genomic platforms and
showed that the actual performance of a microarray depends not
only on the spacing of probes but also on the noise and sensitivity of
copy number variation calls. In particular, the number of consecu-
tively spotted sequences needed to detect a reliable CNV affects the
resolution power.22 Coe et al,29 introduced the term ‘functional
resolution’ to indicate the actual performance of a microarray-based
platform, which is also estimated considering the uniformity of
element spacing on the array and the sensitivity of each platform to
single-copy alterations.
In our study, the high-resolution SNP array GeneChip 6.0
(Affymetrix) sensitivity in identifying copy number changes was tested
by analyzing 19 patients previously shown positive and 51 patients
who were negative to copy number analyses on Agilent lower-resolu-
tion arrays. Data were processed using selection criteria, and CNVs
smaller than 75 kb and represented by less than 80 targets were
excluded. These parameters are appropriate, but may become less
rigorous with the decreasing size of imbalances. The parameters used
could be useful to screen patients with phenotypes suggestive of
genomic imbalance, although they may very likely underestimate the
detection of very small CNVs. Using this approach, we found only one
false-positive CNV mapping to Xq13.1, spanning 0.140Mb, which was
not confirmed by other techniques (patient 5; Table 1). Moreover,
small CNVs with an average length of several Kbs cover about 12% of
the normal human genome,11 and it is difficult to assess whether they
have any clinical consequence.30 To optimize the management of CNV
analyses, a workflow for clinical practice was published by Koolen
et al.24 In our study, these guidelines were followed to further select
the most likely pathogenic CNVs, and it was shown that more than
80% of CNVs detected by high-resolution platforms were poly-
morphic, nonpathogenic copy number changes. In particular, we
found that 100% of CNVs showing a length lower than 100Kb
completely overlapped to polymorphic genomic regions. No false
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negatives were recorded in our study, as all previously detected CNVs
were identified by SNP arrays (SET I). These CNVs were regarded as
pathogenic, as they either corresponded to known regions involved in
microdeletion/microduplication syndromes and/or were quite large
imbalances encompassing several genes, suggesting a causal relation-
ship with the phenotype. The imbalance size and gene content are
important parameters to be considered while assessing the pathogenic
role of CNVs.24,31 Moreover, for 12 of our 19 positive patients it was
possible to trace the CNVorigin, and only 1 was found to be inherited
(patient 12). This was a male patient hemizygous for an Xp22.31
duplication inherited from his unaffected mother. The duplication was
because of a nonhomologous allelic recombination event among
members of the VCX/Y gene family flanking the rearranged segment.
The reciprocal deletion of this genomic segment is associated with
80–90% of X-linked icthyosis/MR cases32 and this duplication was
reported in a child with MR,28 although its pathogenicity has not been
definitely proved.33
Microarray analysis showed that chromosome anomalies detected
by standard and molecular cytogenetic techniques may uncover more
complex rearrangements resolved by CNV studies. For example, in
patient 5, two duplications of about 6 and 3.5Mb on chromosome 5q
were detected. The patient was affected by developmental delay
associated with dysmorphic features, and harbored an apparently
balanced translocation involving chromosomes 3q and 11q. As the
translocation was inherited from the unaffected father, in the begin-
ning it was not considered to be related to the patient’s phenotype.
Integrated microarray and FISH analyses showed that the patient was
heterozygous for duplications resulting from a malsegregation of a
more complex balanced paternal rearrangement, involving chromo-
somes 3, 5 and 11. In patient 17, deletion of the 1pter region was
diagnosed by FISH-based subtelomeric investigation. However, the
patient’s clinical features only partly overlapped the phenotype
of a 1p36 deletion syndrome,34 prompting microarray analysis to
further characterize the rearrangement. CNV analysis confirmed
a 1.4-Mb deletion of the subtelomeric region of 1p36.33, which was
smaller compared with the one usually associated with the 1p36.33
syndrome.35 Array-based analysis also disclosed a 1.6-Mb duplication
of a contiguous 1p36.32 segment (Figure 1). This duplication was
reported previously in association with a 1p36 deletion,36 and it is
likely that its frequency has been underestimated lacking appropriate
diagnostic techniques. Both the size of the deleted segment
and the cooccurrence of the duplication could well explain the atypical
clinical features of this patient, including distinct facial appearance
and absent heart defects and seizures.34 Interestingly, the Affymetrix
SNP platform detected these imbalances, but the CNV overlapping
rate indicated that these copy number changes were neutral
polymorphisms (Table 1). Recent data suggest that the total genomic
content of known common human CNVs in databases is overesti-
mated.37 Therefore, caution should be exercised while interpreting
the significance of the CNV rate, especially for changes involving
large genomic areas particularly rich in small polymorphic CNV
segments.
Figure 1 Patient 17: (a) Subtelomeric deletion of the 1p36.33 region disclosed by fluorescence in situ hybridization (FISH) analysis (arrow). (b) Single-
nucleotide polymorphism (SNP) array analysis shows the deletion (red bar and arrow), followed by the duplication of a contiguous segment (blue bar and
arrow). Although copy number segment analysis indicates a simple gain, the CN state (pink line) suggests that a part of the duplicated region could present
a triplication, may be because of the high copy number variability of this region (c) FISH analysis on interphase nuclei shows the inverted duplication of the
1p36.33p36.32 region (arrows).
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The increased resolution provided by SNP array platforms provides
an increased ability to detect small CNVs. In our cohort of patients,
six additional copy number changes were detected, including four
imbalances, which may be considered pathogenic, but further studies
are required to substantiate this contention. In particular, SNP arrays
disclosed likely causative CNVs in three patients regarded as normal
on the basis of previous CNV analyses. This means that B6% of
patients belonging to the present SET II were found to be affected by a
‘genomic disorder’. In patient 29, a duplication at Xp11.4 involving the
TSPAN7 (OMIM 300096) gene was detected (Figure 3a). TSPAN7
mutations have been associated with X-linked nonsyndromic MR, and
a duplication of this gene has been reported in three patients,38
although the pathogenic function of copy number gains remains
controversial. In our case, parents were not available to assess the
origin of these CNVs, but in structural abnormalities of the X
chromosome, females presenting with a random X-inactivation
pattern is associated with a severe phenotype.39 SNP array analysis
in patient 54 disclosed a loss at 9q33.1 including ASTN2 and TRIM32
genes. ASTN2 is highly expressed in the central nervous system and a
relationship with schizophrenia was suggested recently.40 TRIM32 has
been associated with the Bardet–Biedl syndrome 11 (BBS11; OMIM
209900). Considering that the inheritance of this disorder was
hypothesized to be triallelic, it can be surmised that TRIM32 hetero-
zygotes contribute to the BBS phenotype, whereas a deletion of this
gene can result in a distinct phenotype. In patient 66, 4q21.1
duplication encompassed the ANKRD56, SEPT11 and CCNI genes.
Parental FISH and qPCR analyses showed the de novo origin of CNV.
However, the role of these genes is not clear at present, thus preventing
the possibility of establishing a correlation between their overexpres-
sion and the patient’s phenotype. Notably, the SEPT11 gene was
Figure 2 (a) Duplications at 5q31 and 5q34 (patient 5) identified by single-nucleotide polymorphism (SNP) arrays and indicated by blue bars and arrows.
(b) Fluorescence in situ hybridization (FISH) analysis shows that duplicated segments map to chromosomes involved in a paternal translocation: in particular,
the 5q31 region is partially translocated onto the derivative chromosome 3 (not shown) and is partially translocated onto the derivative chromosome 11 at
11q23.3 (top); 5q34 is translocated onto the derivative chromosome 3 at 3q25.3 (bottom). (c) Left: FISH analysis shows a complex translocation involving
chromosomes 3, 5 and 11 in the patient’s father as described in ideograms (right).
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shown to be expressed in CNS, both in cell bodies and dendrites,41,42
and septins are GTP-binding proteins interacting with developing
myelin structures.43
No mosaic genomic alteration was found in our cohort of patients,
either indicating that mosaic imbalances are a very rare cause of MR/
MCA or reflecting the low sensitivity of the SNP array platform to
detect CNVs in samples containing different cell populations. This
point was discussed by Zhang et al,44 who compared different high-
resolution microarrays and observed that some platforms, including
the Affymetrix SNP array, could escape the detection of mosaic cases
because of data noise.
In summary, genomic microarrays are important tools for studying
patients with idiopathic MR. The opportunity of identifying very
small imbalances using high-resolution microarray platforms
improves our ability to detect the genetic defects responsible for rare
forms of MR. However, this opportunity should be weighed against
the detection of false positives and small CNVs devoid of any obvious
pathogenic effect, including CNVs inherited from unaffected parents.
Therefore, stringent parameters must be used for data analysis, and
parents’ DNA should be available whenever these genomic platforms
are used for diagnostic purposes.
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